When: Close <$88.29 (200 SMA) on volume >15M

Then: Exit remainder of position

When: $88.86/$88.29 SMA cluster with MACD histogram turning positive

Then: First sign of bullish repair; re-evaluate sizing

Trim 10-15%, set trailing stop at $88.86 (50 SMA), hold and let fundamentals work; re-enter fresh capital at $89.99 band zone if adding back

• Stop at $94.75 (current trader plan) is only $3 above current price $91.75; any positive news day triggers stop-out while thesis remains intact
• Conservative stop should be $88.86 (50 SMA) where structural argument actually breaks
• Technical structure shows healthy pullback in uptrend: golden cross, price above 50 SMA ($88.86) and 200 SMA ($88.29), both averages rising, RSI neutral at 51.79
• MACD decayed from 2.61 (late August) to 0.90; momentum decay after 28% rally from $73, not breakdown
• Q1 FY27 fundamentals accelerating: revenue +13.7% YoY, EPS +40.7% YoY, FY27 guidance raised, FDA clearance for LigaSure on Hugo, hired ex-CEO of Recor Medical for Interventional Cardiology
• 7 positive catalysts in 7 days, zero negative news flow; selling into fundamental strength contradicts management confidence
• Valuation reasonable at 14.3x forward on 58% EPS growth; Q1 print confirms trajectory is already being executed
• Bearish case requires MDT to miss by 3-7% in 3 consecutive quarters while losing EP share to BSX (down 57% on the year)
• Beta 0.574 defensive dividend payer; FCF covers dividend at 1.3x; 3.13% yield is real compounding return
• Wrong asset class for macro/trifecta trades; if wanting USD strength/tariff risk/AI rotation exposure, go short tech or cyclicals not defensive healthcare

→ vs aggressive: Central claim of 'high-conviction asymmetric trade' is actually a momentum call disguised as risk management; stop at $94.75 (only $3 above $91.75 current price) means any single positive catalyst (peer downgrade, volume update, Fed whisper, analyst upgrade) triggers stop-out before thesis can realize

→ vs aggressive: Peer-relative argument actually argues opposite direction; if being relative-value conscious during BSX capitulation (down 57% on year), should buy MDT as the relative winner

→ vs neutral: Neutral's own technical report calls for HOLD with buy-on-dip; the golden cross, price above both major MAs, neutral RSI, and constructive consolidation near highs support hold not 25-40% trim

Trim 15-20% of existing MDT exposure over 1-2 weeks; set trailing stop at 88.86 on remaining position; do not initiate new long exposure above 90 without confirmation; re-evaluate on either a 50 SMA hold with MACD histogram recovery or a decisive break below 88.86 with volume.

• Aggressive's distribution call is premature: no volume confirmation, no RSI divergence, MACD line still positive at 0.90, and golden cross intact
• Valuation concern is valid: 14.3x forward P/E implies 58% EPS growth vs Q1 FY27 print of 40.7%, creating execution risk
• Aggressive's peer-relative argument inverted incorrectly: institutional flows rotating into MDT as EP share gainer against BSX suggests 'barely moved' is consolidation at strength, not distribution
• Conservative correctly identified broken stop placement at 94.75 (above entry at 93 and current price at 91.75); proper stop belongs at 88.86 (50 SMA)
• Conservative underestimates MACD deterioration: histogram widening from minus 0.18 to minus 0.31 over two weeks with two failed resistance tests is a genuine warning
• Conservative's seven positive catalysts don't address execution risk, particularly goodwill exposure, which the Aggressive correctly raised
• Balanced trim of 15-20% locks in post-rally gains without abandoning a position with accelerating fundamentals, raised EPS floor, intact golden cross, and 3.13% dividend yield at 1.3x FCF coverage
• Do not initiate new longs at 91.75 with MACD rolling over and two failed resistance tests; wait for breakout above 94.32 or pullback to 89.99-88.86 zone
• Macro supports holding: Polymarket pricing Fed cut odds at 1% through October and 3% through December keeps healthcare defensives bid; AI rotation is real sector-level pressure justifying trim, not exit
• Core error by both sides: treating this as a tactical momentum trade when it's a strategic defensive holding that has already served its portfolio role

→ vs aggressive: Distribution call lacks technical confirmation: zero volume expansion on downside, no RSI divergence, MACD line at 0.90 still in positive territory, golden cross fully intact, and calling the top 3% off highs is impatience, not conviction. Valuation range of 78-85 is presented as 'arithmetic' but is actually a directional bet that consensus is wrong by 15-20%.

→ vs aggressive: Peer-relative argument inverted incorrectly: relative-value trades work by buying the relative winner during peer capitulation, so 'barely moved' during BSX's 57% decline is consolidation at strength, not distribution. No evidence of actual selling pressure provided.

→ vs conservative: MACD deterioration dismissed as routine when it shouldn't be: histogram widening from minus 0.18 to minus 0.31 over two weeks with price failing at resistance twice in a row is a genuine warning, not a healthy pullback. The technical report itself calls bias HOLD with buy-on-dip, suggesting even analysts who wrote it don't see a clean setup.

→ vs conservative: Seven positive catalysts cited as if absence of negative news is a buy signal, but absence of negative news means the bar for disappointment is low. The 14.3x forward multiple prices in execution, and execution risk (especially goodwill exposure) was correctly raised by the Aggressive and not addressed.

→ vs conservative: Both missed the tariff and USD strength concerns the Aggressive raised; while slow-moving rather than immediate triggers, they represent meaningful tail risk that the Conservative's passive stance ignores.